In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN – Research Report), ...

Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel), ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

Carvykti (ciltacabtagene autoleucel) is a prescription drug used to treat certain types of multiple myeloma. Carvykti comes as a liquid suspension for intravenous (IV) infusion given just one time.

RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) revealed findings from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) significantly improves overall ...